ABSTRACT
In response to the SARS-CoV-2 Delta variant, which partially escaped the vaccine-induced immunity provided by two doses of vaccination with CoronaVac (Sinovac), the National Vaccine Committee recommended the heterologous CoronaVac-ChAdOx1 (Oxford−AstraZeneca), a prime−boost vaccine regimen. This pilot study aimed to describe the immunogenicity and adverse events of the heterologous CoronaVac-ChAdOx1 regimen, in comparison with homologous CoronaVac, and homologous ChAdOx1. Between May and August 2021, we recruited a total of 354 participants from four vaccination groups: the CoronaVac-ChAdOx1 vaccinee (n = 155), the homologous CoronaVac vaccinee (n = 32), the homologous ChAdOx1 vaccinee (n = 47), and control group of COVID-19 patients (n = 120). Immunogenicity was evaluated by measuring the level of IgG antibodies against the receptor-binding domain (anti-SRBD) of the SARS-CoV-2 spike protein S1 subunit and the level of neutralizing antibodies (NAbs) against variants of concern (VOCs) using the plaque reduction neutralization test (PRNT) and pseudovirus neutralization test (pVNT). The safety profile was recorded by interviewing at the 1-month visit after vaccination. The anti-SRBD level after the second booster dose of the CoronaVac-ChAdOx1 group at 2 weeks was higher than 4 weeks. At 4 weeks after the second booster dose, the anti-SRBD level in the CoronaVac-ChAdOx1 group was significantly higher than either homologous CoronaVac, the homologous ChAdOx1 group, and Control group (p < 0.001). In the CoronaVac-ChAdOx1 group, the PRNT50 level against the wild-type (434.5 BAU/mL) was the highest; followed by Alpha variant (80.4), Delta variant (67.4), and Beta variant (19.8). The PVNT50 level was also found to be at its highest against the wild-type (432.1); followed by Delta variants (178.3), Alpha variants (163.9), and Beta variant (42.2), respectively. The AEs in the CoronaVac-ChAdOx1 group were well tolerated and generally unremarkable. The CoronaVac-ChAdOx1 heterologous regimen induced higher immunogenicity and a tolerable safety profile. In a situation when only CoronaVac-ChAdOx1 vaccines are available, they should be considered for use in responding to the Delta variant.
ABSTRACT
BACKGROUND: The Institute of Dermatology Thailand in cooperation with the hospitals across the country had conducted the psoriasis patient registry in Thailand between 2005 and 2008. OBJECTIVE: To explore the epidemiology of psoriasis, distribution of disease and type of psoriasis in Thailand, and establish the systematic psoriasis database in Thailand. MATERIAL AND METHOD: This patient registry recorded the demographic, severity and quality of life of psoriasis patients. The patients will be assessed for the severity and asked to complete the questionnaire only one time of enrollment. RESULTS: There have been 11,548 patients enrolled from 32 dermatological centers across Thailand. The male:female ratio was 1.3:1. The chronic plaque type is the majority of psoriasis type (85.6%). The average age of onset is 32.88 years and females have an earlier age of onset than males. Mostly is early onset type of psoriasis (64.2%). Head, body, and leg are the first three ranks of area of skin lesion at first onset. Twenty-five percent of patients have been rated as moderate-to-severe psoriasis as rated by BSA. Fifty-six point six percent of patients report that psoriasis has an impact to their quality of life. The most exacerbating factors are weather, stress, and alcohol drinking. About half of the population reported that they feel embarrassed and are distressed. CONCLUSION: This registry establishes the first systematic psoriasis patient database in Thailand. With it, the epidemiology of psoriasis in Thailand is better understood.
